We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance
News

Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance

Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance
News

Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Achieves Milestone Payment in Rheumatoid Arthritis Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV announced has achievement of a milestone under its alliance agreement in rheumatoid arthritis with Janssen Pharmaceutica NV. The milestone triggered a cash payment of €3.4 million to Galapagos.

In October 2007, Galapagos announced an alliance agreement with Janssen providing Janssen with option rights to acquire worldwide, commercial licenses to novel small molecules from up to 12 of Galapagos' internal programs involving rheumatoid arthritis therapeutic targets. The milestone is the result of one of these programs reaching the next phase of medicinal chemistry optimization.
Advertisement